BioSpace News Archive

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced expanded availability of its Deep Transcranial Magnetic Stimulation technology in South Korea.

Phio Pharmaceuticals Corp. today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common stock of the Company originally issued in October 2018 through June 2023.

Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.

Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of AATD.

Hepion Pharmaceuticals, Inc. today announced that its Board of Directors has approved a strategic restructuring plan with the objective of preserving capital by initially reducing operating costs by approximately 60% going forward.

TransThera Sciences today announced that an oral presentation of tinengotinib clinical data in breast cancer was delivered at 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting.

AbelZeta Pharma Inc. today announced an agreement with AstraZeneca to co-develop C-CAR031.

NextPoint Therapeutics today announced the acceptance of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) for NPX887.

Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.